Overview

A Study Comparing the Clinical Benefit of Finerenone Versus a Fixed Dose Combination (FDC) of Extended-Release Torsemide and Spironolactone in Patients With Hypertension and Chronic Kidney Disease

Status:
RECRUITING

Trial end date:
2026-10-01

Target enrollment:

Participant gender:

Summary

A study Comparing the Clinical Benefit of Finerenone Versus a Fixed-Dose Combination (FDC) of Extended-Release Torsemide and Spironolactone in Patients with Hypertension and Chronic Kidney Disease.

Phase:

PHASE3

Details

Lead Sponsor:

Sarfez Pharmaceuticals, Inc.

Treatments:

finerenone